publication date: Dec. 20, 2010

In this issue: 

FDA approval of Abraxane sets stage for competition between taxane drugs. Abraxane a nanotechnology drug? Sponsor says yes, FDA says.

Also in this 8-page issue: NCI seeks $6.17 billion in “bypass” budget request, but faces shortfall in its actual budget.

NCI names 15 to Director’s Consumer Liaison Group.

SAIC-Frederick makes awards to proteomics research teams.

Latest state cancer statistics released.

Smokers may get cessation help from Medicare.

Funding opportunities listed.

Download (PDF 356KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.